Outlook blindsided as FDA blocks wet AMD drug once again Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.

Shares in #OutlookTherapeutics lost more than half their value after the #FDA turned down the company's marketing application for its new formulation of bevacizumab gamma as a treatment for wet age-related macular degeneration (#wetAMD).

US FDA declines to approve Outlook Therapeutics’ drug for eye condition (Reuters) -Outlook Therapeutics said on Thursday the U.S. health regulator has declined to approve its experimental drug to treat a type of eye condition, which causes blurred vision, sending its shares slumping nearly 70% before the bell. The U.S. Food and Drug Administration, in its so-called "complete response letter", cited a lack of substantial evidence of effectiveness in the company’s application for the drug, ONS-5010, for treating patients with wet age-related macular degeneration. This is a chronic eye disorder that causes blurred vision or a blind spot in the patient’s visual field, and is the leading cause of blindness among the elderly. The FDA’s decision marks another setback in Outlook’s prolonged efforts to enter the market, following a series of previous challenges. The company had withdrawn its application for the eye disease drug in 2022, after the FDA requested additional information. A year later, the regulator declined to approve the drug, citing manufacturing issues. "While we are very disappointed with this outcome, we intend to meet with the FDA to receive additional clarity on their requirements" to potentially approve ONS-5010, said CEO Bob Jahr. The FDA has recommended Outlook to provide additional data on the efficacy to support its application. The company’s resubmitted application was based on the results from a trial that studied the drug compared to Roche’s treatment Lucentis for improving vision in patients. In the key trial conducted by Outlook to address some of the FDA’s previous concerns, ONS-5010 failed to match Roche’s drug at eight weeks. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Other than Lucentis, the already approved and available treatments for wet age-related macular degeneration include Regeneron’s Eylea and Roche’s Vabysmo. Outlook’s drug, under the brand name Lytenava, is approved in the European Union and the UK for the condition. ProPicks AI evaluates REGN alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if REGN is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

Click Subscribe #FDA #OutlookTherapeutics #Pharmaceuticals #EyeHealth #DrugApproval

Outlook Therapeutics stock falls after FDA rejects wet AMD drug Investing.com -- Outlook Therapeutics (NASDAQ:OTLK) stock plummeted 70% Thursday morning after the U.S. Food and Drug Administration (FDA) rejected its application for ONS-5010/LYTENAVA (bevacizumab-vikg), a treatment for wet age-related macular degeneration (wet AMD). The FDA issued a Complete Response Letter (CRL) to the company’s resubmitted Biologics License Application (BLA), stating it cannot approve the application in its current form due to "lack of substantial evidence of effectiveness." The agency recommended that Outlook submit confirmatory efficacy evidence to support the application after the drug failed to meet its primary endpoint in the NORSE EIGHT clinical trial. The setback comes despite the FDA acknowledging that the company’s earlier NORSE TWO trial had met its primary effectiveness endpoint. The CRL identified no other outstanding deficiencies in the BLA submission. "While we are very disappointed with this outcome, we intend to meet with the FDA to receive additional clarity on their requirements to potentially approve the first on-label bevacizumab product specifically formulated, manufactured, and packaged for intravitreal use in the United States," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. The company plans to work with the FDA to address the agency’s concerns while continuing its expansion efforts in Europe, where LYTENAVA has already received marketing authorization from both the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency. The drug became commercially available in Germany and the UK in June 2025. Outlook Therapeutics is seeking to provide an FDA-approved alternative to compounded Avastin for wet AMD treatment in the United States. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. First, check if it's included in one of this month's AI-powered stock strategies for ProPicks AI. Investing.com created these strategies to identify the most exciting trading opportunities currently in the market. The stocks that made the cut could produce monster returns in the coming years, like ViaSat and Sapiens , both up over 60%+ each in Q2 of 2025 alone. Is OTLK one of them?

Click Subscribe #OutlookTherapeutics #AMD #FDA #pharma #biotech

#OTLK launches Lytenava™ in the EU and UK, offering a new solution for wet age-related macular degeneration (wet AMD). This marks a key step in global vision care innovation.
#OutlookTherapeutics
prismmarketview.com/outlook-ther...

Outlook Therapeutics Receives NICE Recommendation of Lytenava for Wet AMD - Eyewire+ The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lytenava (bevacizumab gamma) as an option for the tr

#OutlookTherapeutics #NICERecommendation #Lytenava #bevacizumabgamma #bevacizumab #WetAMD #ophthalmology #biopharmaceuticals #retinadisease #NICE #NICErecommended #VEGF #WetAMDpatients #NHSEngland #NHSWales #MHRA #NORSEONE #NORSETWO #NORSETHREE #clinicaltrials #Cencora
eyewire.news/news/outlook...